Retroviral protease inhibiting compounds

A combination of pharmaceutical agents for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor.

(2S,3S,5S)-5-(N- (N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)am ino)-2-(N-((5-thiazolyl) methoxycarbonyl)-amino)- 1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor for concomitant administration for the treatment of an HIV infection.

(2S,3S,5S)-5-(N-(N-((N-Methyl-N -((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-t hiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and zidovudine for concomitant administration for the treatment of an HIV infection.

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-th iazolyl)methyl)-amino)carbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhe xane or a pharmaceutically acceptable salt thereof and dideoxycytidine for concomitant administration for the treatment of an HIV infection.

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)meth yl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl) methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and dideoxyinosine for concomitant administration for the treatment of an HIV infection.

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2 -isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiaz olyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and D4T for concomitant administration for the treatment of an HIV infection.

(2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-th iazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycar bonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and BCH-189 for concomitant administration for the treatment of an HIV infection.

A combination pharmaceutical agent for administration to a human for the treatment of an HIV infection comprising:

• a) a first pharmaceutical composition comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and
• b) a second pharmaceutical composition comprising a reverse transcriptase inhibitor.

Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhe xane or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for concomitant administration to a human with a reverse transcriptase inhibitor for the treatment of an HIV infection.